Aims-To examine thymomas for proteins encoded by oncogenes and to determine whether their presence correlates with tumour growth and associated myasthenia gravis. Methods-Sections of 24 thymomas were incubated with anti-EGF receptor (EGF-R), anti-Ki67 antigen, anti-p53, and antibcl-2 antibodies, and then stained using the alkaline phosphatase/anti-alkaline phosphatase (APAAP) technique. Cell suspensions and epithelial cell cultures from some of the tumours were also studied. Results-Whereas EGF-R expression was not detected in any ofthe controls (but only in a 20 week old fetus), it was detected in neoplastic epithelial cells of all thymomas, and was most strongly expressed in metastases and in samples from donors with severe myasthenia gravis. Ki67 labelling was also increased, especially in the larger thymomas. Epithelial expression of both of these markers was confirmed in fresh cell suspensions and monolayer cultures from the five available cases. In contrast, p53 and bcl-2 were not detected in the neoplastic cells, but bcl-2 was present in the intermingling thymocytes. Conclusions-Neoplastic thymoma cells express EGF-R and Ki67, but there is no concomitant increase in the expression of p53 and bcl-2 proteins. Increased EGF-R expression may result in increased proliferation of neoplastic cells and also in myasthenia gravis. Measurement of EGF-R concentrations may be of prognostic value. The bcl-2 staining pattern in T lymphocytes illustrates the broad spectrum of maturational stages in thymoma lymphocytes. (J7 Clin Pathol 1995;48:447-455) 
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Tumours arise through alterations in cell division or cell death, or both. Control of cell multiplication is exerted by very diverse positive and negative cell proliferation signals, and aberrations in genes encoding either are crucial in tumorigenesis.' Increased expression of a proto-oncogene product such as the epidermal growth factor receptor (EGF-R) will promote cell growth. Ligands binding to this surface membrane receptor activate its intracellular tyrosine kinase and thereby increase the mitotic rate of the cell.2 EGF-R expression is also increased in several epithelial tumour cell types.' Another proto-oncogene, bcl-2, encodes two proteins of the inner mitochondrial membrane that extend cell survival by blocking programmed cell death (apoptosis)4; bcl-2 proteins were originally found only in B and T cells but have now 16 For indirect immunofluorescence, cell suspensions were incubated with first layer monoclonal antibodies, washed, and then with class specific second layer anti-immunoglobulin antibodies (see later), before washing and analysis by fluorescence microscopy or on a fluorescence activated cell sorter (FACScan, Becton Dickinson, USA). Cell suspensions were sometimes cytocentrifuged and stained with a second antibody and conjugate after fixation.
THYMOMA CULTURES
Neoplastic epithelial cells were cultured from four fresh thymomas and from one of nine cryopreserved suspensions.14 Cells were cultured for eight to 10 weeks and were 85-95% pure. Samples grown on coverslips were fixed in 95% methanol before being stained for intracellular antigens by indirect immunofluorescence. Both the frequency of positive cells and the staining intensity were recorded. In some experiments cells were cultured in interferon-y 500 U/ml (British Biotechnology, Oxford, UK) for 72 hours before staining.
ANTIBODIES
The mouse monoclonal antibodies used in this study are (fig 4) . This staining did not correlate with the in vitro growth rate and was not restored by culture with interferon-y.
KI67
In the control sections Ki67 stained many nuclei in the cortex (20-40%), but only a small minority in the medulla (1-5%) (fig 5a) . Nearly all of the positive cells were thymocytes. Their overall frequency was similar in the fetal thymus, but the distinction between cortical and medullary areas was less obvious.
In thymoma sections nuclear labelling for Ki67 showed either an even staining pattern that was strongest along the nuclear membrane (APAAP) (figs 5b and 5c), or a more granular pattern (immunofluorescence) (figs 6a and 6b). Ki67 staining was highly variable both within and between tumours. In most there were areas with either high (10-70%) or low (0-5%) pro (table 2), but positively with tumour size; in four of the six small thymomas staining was weak (+ -+ +), but was intense (+ + + +) in four of the nine large tumours and weak in only one of them. Ki67 staining was not especially increased in the invasive or metastatic tumours, or in those with the best growth in culture, and did not correlate with clinical parameters of myasthenia gravis. The proportion of Ki67 positive cells tended to be higher in the thymomas with a high total yield of cell suspension (fig 7) . Cytoplasmic staining by Ki67 was noted in the outer cortex in two of the eight control samples and in 17 None of the cells in the sections from the 24 thymomas or in the five cultures stained for the p53 protein with any of the three different antibodies used. The normal thymus sections were equally negative.
BCL-2 PROTEIN
In control thymic specimens the anti-bcl-2 antibody stained 60-80% of thymocytes in the medulla, but only about 10% in the cortex (fig  8a) . In the fetal sample a similar fraction of the total thymocytes was stained. There was no obvious staining of epithelial cells or of other stromal elements in either. Ki67 ++ Figure 6 Thymomas stained for Ki67 using indirect immunofluorescence: a, tissue section from a mainly polygonal, non-infiltrative thymoma stained with mouse anti-Ki67 and rabbit antikeratin and with fluorescein isothiocyanate and tetrarhodamine isothiocyanate conjugated second layer antibodies, respectively; b, granular nuclear Ki67 staining in a thymoma epithelial spindle cell culture (x 240). Cell yield In the thymoma samples a variable proportion of cells was stained (fig 8b) ; these cells were apparently almost exclusively thymocytes, and no definite epithelial labelling was seen, even in lymphocyte depleted areas. Staining was entirely cytoplasmic and perinuclear. The proportion of cells stained varied between approximately 2% and 60%. It was greater in areas with abundant CD 1 positive and especially CD3 positive T cells. As with Ki67 positive lymphoid cells, the proportion stained was also higher in the thymomas with a high total yield of cells in suspension (>2 x 109 cells per cm3 tumour). However, this did not correlate with other aspects of epithelial cell growth or with the presence of myasthenia gravis. None of the five cultures of thymoma epithelial cells stained for bcl-2. Discussion This paper shows for the first time that neoplastic epithelial cells in thymomas express the oncogene protein EGF-R and the proliferation marker Ki67, with no increase in p53 or bcl-2 protein expression, even in metastases. Thymus from infants was chosen as the normal control because thymomas resemble it much more closely than the adult thymus both in lymphocellularity and bulk. These samples, however, showed no epithelial labelling for EGF-R, which was only seen during fetal life when cell proliferation is at its highest. The expression of the Ki67 antigen in a small minority of normal epithelial cells cannot be completely ruled out because of the excess of positive thymocytes. That probably explains why Ki67 labelling in a previous study was noted only in the lymphoid cells ofthymomas.20 Double staining of thymoma cells in situ and in culture conclusively establishes that some neoplastic epithelial cells were positive for Ki67.
In addition to their neoplastic growth thymomas are particularly interesting because of their association with myasthenia gravis. This might reflect sensitisation of developing T cells by epitopes of AcChR'4 or other muscle antigens"3 expressed by the neoplastic epithelial cells. Interestingly, in this study, EGF-R expression tended to be lower where myasthenia was absent or mild, and higher in severe myasthenia gravis. This is not an effect caused by intensive therapy for severe myasthenia gravis as very few of these patients had taken immunosuppressive drugs before thymectomy. It is more probable that in patients with myasthenia gravis neoplastic epithelial cells express not only more EGF-R, but also more of the muscle related antigens, or in a more immunogenic form, and so stimulate a stronger or more diverse response. There was no similar correlation between the severity of myasthenia gravis and thymoma size, invasiveness or other aspects of thymoma growth potential.
Myasthenia gravis accompanied by a thymoma tends to be more severe and has a higher associated mortality. However, we should interpret the results from that small series with caution; prognostication has not proved to be reliable in previous studies using a variety of histological classifications based on corticomedullary differentiation, epithelial or keratin staining, nuclear morphology, or lymphocyte content, although some correlations have been reported. [24] [25] [26] [27] [28] [29] When the EGF-R binds its ligand, its intrinsic tyrosine kinase is activated and cell proliferation is enhanced.2 Its expression is increased in many epithelial tumours, such as those of the lung, breast, and urinary and genital tracts. [30] [31] [32] In some of these, there seems to be a modest correlation between EGF-R expression, dedifferentiation and poor prognosis.33 High EGF-R concentrations have also been detected on human glioma cells.34 Overexpression of EGF-R by thymoma cells is one further sign ofits wide contribution to increased cell proliferation in neoplasia. The growth in culture of human tumour cells expressing high amounts of EGF-R is inhibited by anti-EGF-R antibodies35 and EGF was always used in our thymoma epithelial cell cultures.16 Although the effect ofEGF-R on cell proliferation is, for a large part, mediated by the ras protein,36 ras activation was not found in the only thymoma examined. The p53 protein was not detected in any of the thymomas. As it is usually expressed at undetectable low concentrations in normal tissues, we cannot exclude a decrease in p53 expression in thymomas, perhaps resulting from deletions within the p53 gene. However, increased expression is the more usual result of p53 gene mutations and has been seen in many of the common cancers.744 These mutations convert p53 from a restraining to an enhancing or dysregulatory factor in the control of cell growth. Similarly, it has been suggested that the bcl-2 protein can extend cell survival not only in lymphomas but also in other neoplasias including epithelial tumours.4145 However, our study excludes any major role for bcl-2 in thymoma neoplastic epithelial cells.
The heterogeneous bcl-2 expression observed confirms the broad spectrum of maturational stages in thymoma lymphocytes, as in normal thymocytes. The normal function of the bcl-2 protein is to extend survival in tissues where the life span is limited by apoptosis,4
and it plays a particularly important role in the thymus. When immature thymocytes develop surface T cell receptors, they are very vulnerable to apoptosis, but can be saved by positive selection by the cortical epithelium. This almost certainly acts through bcl-2 and related pathways. 47 The increased Ki67 positive thymocyte frequency in thymomas, observed in this study and in others,20 and their very disorganised architecture imply great scope for aberrations in positive as well as in negative selection. Overexpression of bcl-2 could be a sign of defects in the latter, and could thus lead to the propagation of autoaggressive T cells in thymomas. Moreover, as most Ki67 positive thymocytes are usually also CD45 RO positive and are destined for intrathymic death,48 their abundance in thymomas may be further evidence of selection defects. However, as the spectrum of autoimmune diseases associated with thymomas is so highly restricted, we believe that active sensitisation of specific T cells within these tumours is more likely than abnormally permissive positive selection or generally defective negative selection.
In conclusion, thymoma epithelial cells can overexpress EGF-R which partially correlates with the severity of myasthenia gravis and with tumour invasiveness. This could result from mutations such as those found in many human neoplasms. Together with the increased Ki67 positive frequency in these cells, this may be a sign of the uncontrolled growth that is the hallmark of neoplasia.
